MEDCAC Meeting

Screening Genetic Tests

05/06/2009

Expand All | Collapse All

Issue

On May 6, 2009, CMS will convene a public meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) entitled "Screening Genetic Tests".

The Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) defines genetic testing as "…any test performed using molecular biology methods to test DNA or RNA, including germline, heritable, and acquired somatic variations." Genetic screening test(s) are used for individuals who do not exhibit signs or symptoms of a disorder to detect possible diseases and for clinical uses. Currently, these tests are sweeping into the market despite the less than robust evidence to support these uses.

This meeting will focus on the desirable characteristics of evidence that are needed to evaluate screening genetic test(s) for Medicare coverage. As such CMS wants to determine whether genetic testing as a laboratory screening service improves health outcomes for the Medicare population. Specifically, does the screening genetic testing change the natural history and/or reduce the complications of the disease and alter morbidity/mortality. CMS also asks the committee to identify current data deficiencies that warrant further research.

Actions Taken

February 25, 2009

Announced meeting.

March 17, 2009

Posted Federal Register notice.

March 20, 2009

Posted questions for meeting.

April 30, 2009

Posted roster, agenda and speaker list for meeting.

May 11, 2009

Posted scoresheet from meeting.

July 7, 2009

Posted minutes [PDF, 1MB] and transcript [PDF, 719KB] from meeting.

Agenda

Agenda
Medicare Evidence Development & Coverage Advisory Committee
May 6, 2009
7:30 AM - 4:30 PM
CMS Auditorium

Saty Satya-Murti, Acting Chair
Marcel Salive, MD, Coverage and Analysis Group
Maria Ellis, Executive Secretary


7:30 - 8:00 AM

Registration

8:00 - 8:20 AM

Opening Remarks—Maria Ellis/ Marcel Salive, MD/Saty Satya-Murti, MD

8:20 - 8:40 AM

CMS Presentation & Voting Questions - Sandra Jones, RN/Jeffrey Roche, MD, MPH

8:40 - 9:00 AM

William G. Feero, MD, PhD, Chief, Genomic Healthcare Branch, National Human Genome Research Institute, National Institutes of Health

9:00 - 9:20 AM

Steven Teutsch, MD, MPH, Chief Science Officer, LA County Public Health Department

9:20 - 10:05 AM

Scheduled Public Comments
(Refer to Speaker List)

10:05- 10:20AM

BREAK

10:20 - 10:45 AM

Open Public Comments 
Public Attendees who wish to address the panel will be given that opportunity 

10:45 - 11:30 AM

Questions to Presenters


Public attendees, who have contacted the executive secretary prior to the meeting, will address the panel and present information relevant to the agenda. Speakers are asked to state whether or not they have any financial involvement with manufacturers of any products being discussed or with their competitors and who funded their travel to this meeting.


11:30 - 12:30 PM

LUNCH (on your own)

12:30 - 1:30 PM

Initial Open Panel Discussion: Dr. Satya-Murti

1:30 - 2:30 PM

Formal Remarks and Voting Questions
The Chairperson will ask each panel member to state his or her position on the voting questions

2:30 - 3:30 PM

Final Open Panel Discussion: Dr. Satya-Murti

3:30 - 4:30 PM 

Closing Remarks/Adjournment: Dr. Salive & Dr. Satya-Murti

4:30 PM

ADJOURN

Minutes

Download meeting minutes [PDF, 1MB]

Panel Voting Questions

Issue:

CMS wishes to obtain the MEDCAC’s recommendation regarding the desirable characteristics of evidence that could be used by the Medicare program to determine whether the screening use of genetic testing improves health outcomes or leads to early detection of clinically inapparent disease.  The Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) has defined genetic testing as “…any test performed using molecular biology methods to test DNA or RNA, including germline, heritable, and acquired somatic variations.”

Pursuant to Title XVIII of the Social Security Act (the Act), §1862(a)(1)(A), Congress gave the Secretary of Health and Human Services the authority to consider Medicare coverage of diagnostic tests. Diagnostic tests are used by the treating physician to diagnose or treat a condition or disease when the beneficiary has signs or symptoms of a disorder. In contrast to diagnostic tests, screening tests are administered to asymptomatic individuals for the prevention or early detection of illness or disability. During the last 25 years, Congress has added some screening services that are now covered by Medicare; and these screening services include: mammography, glaucoma, pelvic exam and pap test, diabetes, lipids, colorectal cancer and prostate cancer.

Recently, the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) (Pub. L. 110-275) was approved by Congress. Effective January 1, 2009, MIPPA, section 101(a), provides for Medicare Part B coverage for additional preventive services, that are not already described in Title XVIII of the Act, when the Secretary determines through the national coverage determination (NCD) process (as described in section 1869(f)(1)(B) of the Act) that a new service meets the following statutory requirements for coverage.

(1) The service is reasonable and necessary for the prevention or early detection of an illness or disability;
(2) The United States Preventive Services Task Force (USPSTF) provides a grade A or B recommendation for the service. (The USPSTF recommendations are located at: http://www.ahrq.gov/clinic/uspstfix.htm); and
(3) The service is appropriate for beneficiaries entitled to benefits under Part A or enrolled under Part B.

Currently, Medicare does not have a national coverage decision for screening genetic tests. Since screening is conducted on asymptomatic individuals, the analytic framework for screening tests involves consideration of several different factors compared to diagnostic tests and therapeutic interventions. One framework for evaluating screening tests was outlined by Cochrane and Holland (1971) as follows: “The value of a screening test may be assessed according to the following criteria:

i. Simplicity. In many screening programmes more than one test is used to detect one disease, and in a multiphasic programme the individual will be subjected to a number of tests within a short space of time. It is therefore essential that the tests used should be easy to administer and should be capable of use by para-medical and other personnel.
ii. Acceptability. As screening is in most instances voluntary and a high rate of co-operation is necessary in an efficient screening programme, it is important that tests should be acceptable to the subjects.
iii. Accuracy. The test should give a true measurement of the attribute under investigation.
iv. Cost. The expense of screening should be considered in relation to the benefits resulting from the early detection of disease, i.e., the severity of the disease, the advantages of treatment at an early stage and the probability of cure.
v. Precision (sometimes called repeatability). The test should give consistent results in repeated trials.
vi. Sensitivity. This may be defined as the ability of the test to give a positive finding when the individual screened has the disease or abnormality under investigation.
vii. Specificity. This may be defined as the ability of the test to give a negative finding when the individual screened does not have the disease or abnormality under investigation.”

An example of a genetic test suggested for screening use is detection of the homozygous presence of e4 allele of the APOE gene (also expressed as APOE e4/e4). This genetic characteristic has been shown in published studies to be associated with an elevated risk of developing Alzheimer disease (Odds Ratio 2.1 (95% CI, 5.1-11.9)b). A further discussion of considerations for using this genetic test in a specific clinical scenario is provided in the series of recent articles.

Reference: Attia J, Ioannidis JPA, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, et al. How to use an article about genetic association:
A: background concepts. JAMA 2009 Jan 7; 301(1): 74-81;
B: Are the results of the study valid? JAMA 2009 Jan 14; 301(2): 191-7;
C: What are the results and will they help me in caring for my patients? JAMA Jan 21; 301(3): 304-8.

Questions:

The following questions should be addressed in the context of screening genetic tests for the early detection of disease:

Q1. Are there differences in the desirable characteristics of evidence about screening genetic tests versus those of screening tests in general?

Discussion

Q2. What are the desirable characteristics of evidence for determining the analytical validity of screening genetic tests?

Discussion

Q3A. Beyond aspects of analytical validity, are there meaningful differences in the desirable and/or necessary characteristics of evidence about the effect of genetic testing on outcomes? If yes, please consider question 3 separately for each paradigm.

  • Early detection of disease in an asymptomatic person
  • Early treatment of disease (before signs or symptoms are apparent)

Q3B. What comparative data are needed on alternative strategies for screening?

Q4. For each type of outcome below, how confident are you that methodologically rigorous evidence on the outcome is sufficient to infer whether or not screening genetic testing is effective for the prevention or early detection of illness or disability?

For each lettered outcome type, assign a number from 1 to 5 to indicate your vote. A lower number indicates lower confidence; a higher number indicates higher confidence.

a) Additional (confirmatory) diagnostic procedure

b) Survival

c) Other patient-focused healthcare outcomes e.g., functional status, incidence of adverse events

Q5. What are the desirable measures of the cost-effectiveness of screening genetic tests for the prevention or early detection of illness or disability?

Consider ranking (1=lowest thru 3=highest) the below (a-c) options and/or identify other measures that would be appropriate.

a) Quality-adjusted life years (QALYs) gained due to screening?

b) Decreases in incidence of illness or disability, or net gains in other patient-focused healthcare outcomes?

c) Net changes in lifetime costs of illness or disability?

For discussion.

Q6. What are the desirable methodological characteristics of studies of cost-effectiveness for screening genetic tests for the prevention or early detection of illness of disability?

For discussion.

Q7. Are there ethical issues particular to screening genetic testing that may alter the methodologic rigor of studies of genetic testing?

Please discuss the existence, relevance, and impact of such issues.

Q8. Does the age of the Medicare beneficiary population present particular challenges that may compromise the generation and/or interpretation of evidence regarding genetic testing?

Please discuss the existence, relevance, and impact of such challenges.

Download scoresheet [PDF, 25KB]

Contact Information

Other Material

Roster

May 6, 2009
MEDCAC Roster

Saty Satya-Murti, MD, FANN Acting Chair
Health Policy Consultant

Marion Danis, MD
Chief
Bioethics Consultation Service
NIH Clinical Center

Nancy Davenport-Ennis, BA
CEO
Patient Advocate Foundation

Mark D. Grant, MD, MPH
Associate Director
Technology Evaluation Center
BlueCross BlueShield Association

Daniel F. Hayes, MD
Clinical Director
Breast Oncology Program
Stuart B. Padnos
Professor in Breast Cancer Research
University of Michigan Comprehensive Cancer Center

I. Craig Henderson, MD
Adjunct Professor of Medicine
University of California, San Francisco

James E. Puklin, MD
Professor of Ophthalmology
Department of Ophthalmolgy
Kresge Eye Institute
Wayne State University School of Medicine

Randal Richner, BSN, MPH
President and Founder
Neocure Group, LLC

Maren T. Scheuner, MD, MPH
RAND Corporation

Teresa M. Schroeder, BS, MBA
Director
Clinical Affairs
Musculoskeletal Clinical Regulatory
Advisers, LLC

John Spertus, MD, MPH, FACC
Director
Cardiovascular Education and Outcomes
Research
Mid America Heart Institute
University of Missouri

Steven Teutsch, MD, MPH
Chief Science Officer
LA County Public Health Department

Jonathan P. Weiner, PhD
Professor
Health Policy & Management
Johns Hopkins University
Bloomberg School of Public Health

Industry Representative
Eleanor M. Perfetto, PhD, MS
Senior Director
Evidence Based Strategies
Pfizer, Inc.

Guest Panelist
Steve Gutman, MD
Professor of Pathology
University of Central Florida

Neil Holtzman, MD
Professor
Johns Hopkins Bloomberg School of Public Health

Elizabeth Mansfield, PhD
Senior Genomics Advisor
OSMP, Office of the Chief Scientist
Food and Drug Administration

Guest Speakers
W. Gregory Feero, MD, PhD
Chief
Genomic Healthcare Branch
National Human Genome Research
National Institute of Health

CMS Liaison
Marcel Salive, MD
Director
Division of Medical & Surgical Services
Coverage and Analysis Group

Executive Secretary
Maria A. Ellis

Speaker List

Medicare Evidence Development & Coverage Advisory Committee
May 6, 2009

SPEAKER LIST

* 7 MINUTES PER SPEAKER*

  • Jan A. Nowak, MD, PhD, FCAP, Medical Director, Molecular Diagnostics Laboratory, Evanston Hospital
  • Richard Wenstrup, MD, Chief Medical Officer, Myriad Genetic Laboratories, Inc.
  • Bruce Quinn, MD, MBA, Senior Health Policy Specialist, Foley Hoag, LLP
  • Charis Eng, MD, PhD, FACP, Chairman and Director, Cleveland Clinic Genomic Medicine Institute
  • Diane J. Allingham-Hawkins, PhD, FCCMG, FACMG, Director, Genetics Test Evaluation Program, Hayes, Inc.
  • Roger D. Klein, MD, JD, Medical Director, Molecular Oncology, Blood Center of Wisconsin

Associated NCA

Associated Technology Assessment